Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis.

Rawool DB, Bitsaktsis C, Li Y, Gosselin DR, Lin Y, Kurkure NV, Metzger DW, Gosselin EJ.

J Immunol. 2008 Apr 15;180(8):5548-57.

2.

In vivo mechanisms involved in enhanced protection utilizing an Fc receptor-targeted mucosal vaccine platform in a bacterial vaccine and challenge model.

Bitsaktsis C, Babadjanova Z, Gosselin EJ.

Infect Immun. 2015 Jan;83(1):77-89. doi: 10.1128/IAI.02289-14. Epub 2014 Oct 13.

4.

Downmodulation of vaccine-induced immunity and protection against the intracellular bacterium Francisella tularensis by the inhibitory receptor FcγRIIB.

Franz BJ, Li Y, Bitsaktsis C, Iglesias BV, Pham G, Sunagar R, Kumar S, Gosselin EJ.

J Immunol Res. 2015;2015:840842. doi: 10.1155/2015/840842. Epub 2015 Apr 19.

5.

Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs.

Anderson RV, Crane DD, Bosio CM.

Vaccine. 2010 Sep 14;28(40):6562-72. doi: 10.1016/j.vaccine.2010.07.072. Epub 2010 Aug 3.

6.

Multiple mechanisms mediate enhanced immunity generated by mAb-inactivated F. tularensis immunogen.

Iglesias BV, Bitsaktsis C, Pham G, Drake JR, Hazlett KR, Porter K, Gosselin EJ.

Immunol Cell Biol. 2013 Feb;91(2):139-48. doi: 10.1038/icb.2012.66. Epub 2012 Dec 18.

7.

Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A.

Ray HJ, Cong Y, Murthy AK, Selby DM, Klose KE, Barker JR, Guentzel MN, Arulanandam BP.

Clin Vaccine Immunol. 2009 Apr;16(4):444-52. doi: 10.1128/CVI.00405-08. Epub 2009 Feb 11.

8.

Identification of a live attenuated vaccine candidate for tularemia prophylaxis.

Mahawar M, Rabadi SM, Banik S, Catlett SV, Metzger DW, Malik M, Bakshi CS.

PLoS One. 2013 Apr 17;8(4):e61539. doi: 10.1371/journal.pone.0061539. Print 2013.

9.

Targeting of a Fixed Bacterial Immunogen to Fc Receptors Reverses the Anti-Inflammatory Properties of the Gram-Negative Bacterium, Francisella tularensis, during the Early Stages of Infection.

Babadjanova Z, Wiedinger K, Gosselin EJ, Bitsaktsis C.

PLoS One. 2015 Jun 26;10(6):e0129981. doi: 10.1371/journal.pone.0129981. eCollection 2015.

10.

Fc receptor-targeting of immunogen as a strategy for enhanced antigen loading, vaccination, and protection using intranasally administered antigen-pulsed dendritic cells.

Pham GH, Iglesias BV, Gosselin EJ.

Vaccine. 2014 Sep 8;32(40):5212-20. doi: 10.1016/j.vaccine.2014.07.050. Epub 2014 Jul 26.

11.

Interleukin-17 protects against the Francisella tularensis live vaccine strain but not against a virulent F. tularensis type A strain.

Skyberg JA, Rollins MF, Samuel JW, Sutherland MD, Belisle JT, Pascual DW.

Infect Immun. 2013 Sep;81(9):3099-105. doi: 10.1128/IAI.00203-13. Epub 2013 Jun 17.

12.

Models derived from in vitro analyses of spleen, liver, and lung leukocyte functions predict vaccine efficacy against the Francisella tularensis Live Vaccine Strain (LVS).

De Pascalis R, Chou AY, Ryden P, Kennett NJ, Sjöstedt A, Elkins KL.

MBio. 2014 Apr 8;5(2):e00936. doi: 10.1128/mBio.00936-13.

14.

Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.

Richard K, Mann BJ, Qin A, Barry EM, Ernst RK, Vogel SN.

Clin Vaccine Immunol. 2017 Mar 6;24(3). pii: e00574-16. doi: 10.1128/CVI.00574-16. Print 2017 Mar.

17.

Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (DeltaiglB) induces protective immunity against homotypic and heterotypic challenge.

Cong Y, Yu JJ, Guentzel MN, Berton MT, Seshu J, Klose KE, Arulanandam BP.

Vaccine. 2009 Sep 18;27(41):5554-61. doi: 10.1016/j.vaccine.2009.07.034. Epub 2009 Aug 3.

18.

Vaccination evokes gender-dependent protection against tularemia infection in C57BL/6Tac mice.

Sunagar R, Kumar S, Franz BJ, Gosselin EJ.

Vaccine. 2016 Jun 17;34(29):3396-404. doi: 10.1016/j.vaccine.2016.04.054. Epub 2016 May 13.

19.

Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis.

Troyer RM, Propst KL, Fairman J, Bosio CM, Dow SW.

Vaccine. 2009 Jul 16;27(33):4424-33. doi: 10.1016/j.vaccine.2009.05.041. Epub 2009 May 31.

20.

An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Bakshi CS, Malik M, Mahawar M, Kirimanjeswara GS, Hazlett KR, Palmer LE, Furie MB, Singh R, Melendez JA, Sellati TJ, Metzger DW.

Vaccine. 2008 Sep 26;26(41):5276-88. doi: 10.1016/j.vaccine.2008.07.051. Epub 2008 Aug 8.

Supplemental Content

Support Center